ArticleJournal of inflammation research2025
Exploring
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Berberine alleviates biofilm-associated immune-inflammatory injury inFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adenomyosis is a chronic inflammatory gynecological disorder closely linked with diminished fertility potential that poses significant challenges in pharmacological management. Methods: Ultra-performance liquid chromatography coupled with Q Exactive™ HF-X mass spectrometry (UPLC-QE-MS) was employed to identify the constituents of DS. Targets for DS in treating adenomyosis were identified from various databases and a PPI network was constructed. Core target genes were identified by Module analysis using MCODE and CytoNCA plugin of Cytoscape. Functional analyses of core target genes were performed using GO and KEGG, followed by molecular docking, transcriptomics validation, and molecular dynamics simulations. Predicted targets and pathways were validated through Western blotting, qRT-PCR, and IF. Results: Thirty-five potential bioactive components from ingredients absorbed into the bloodstream (IAIBs) of DS were identified. Network pharmacology predicted that DS might exert therapeutic effects on adenomyosis by modulating the TNF-α/IL-17/HIF-1α signaling pathways through key targets, including Conclusion: This study initially emphasizes the potential of DS in addressing adenomyosis by concurrently targeting an anti-inflammatory network involving the TNF-α/HIF-1α/IL-17 signaling pathways, supporting its development as a phytotherapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.